#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response	0.5						

longer subject to Section 16. Form 4 or Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)													
1. Name and Address of Reporting Person Noble James  (Last) (First) (Middle)  BROCK HOUSE, SHEEPDROVE, LAMBOURN					2. Issuer Name and Ticker or Trading Symbol     Adaptimmune Therapeutics PLC [ADAP]     3. Date of Earliest Transaction (Month/Day/Year)     01/04/2019						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_ Director 10% Owner X_ Officer (give title below) Other (specify below)  Chief Executive Officer				
				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X. Form filed by One Reporting Person _Form filed by More than One Reporting Person			
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned				
(Instr. 3)			2. Transaction Date (Month/Day/Ye	2A. Deemed Execution Date, if Coor (Insumplement) (Month/Day/Year)				8) (1	A) or Disposed on nstr. 3, 4 and 5)  (A) or mount (A) or (D)	of (D) Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: 1	Report on a s	eparate line for each	class of securities b	II - Deri	vativ	ve Securities	Acqı	Persons this for current	s who respond m are not requ by valid OMB of sed of, or Bene nvertible securi	uired to rescontrol num	spond unles mber.			in SEC	1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	on See (Month/Day/Year) E au	Execution Date, if	4. Transaction Code		5. Number of		6. Date Exercisable and Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported		(Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction( (Instr. 4)	(I) (Instr. 4)	
Option to purchase Ordinary Shares	\$ 0.89 (1)	01/04/2019		A		2,515,536		(2)	01/04/2029	Ordinary Shares	2,515,536	\$ 0	2,515,536	5 D	
Option to purchase Ordinary Shares	\$ 0.0013	01/04/2019		A		561,792		(4)	01/04/2029	Ordinary Shares	561,792	\$ 0	561,792	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Noble James BROCK HOUSE, SHEEPDROVE, LAMBOURN HUNGERFORD, X0 RG17 7XA	X		Chief Executive Officer				

## **Signatures**

/s/ James Noble	01/08/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price was converted from GBP0.70 based on an exchange rate of \$U.S. 1.26332 GBP1.00. The actual exercise price will be the pounds sterling amount.

- (2) Exercisable as to 628,884 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 52,512 Ordinary Shares on January 4, 2023.
- (3) The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of \$U.S. 1.26332 GBP1.00. The actual exercise price will be the pounds sterling amount.
- (4) Exercisable as to 140,448 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.